# Expanded Access Program for GBM Subjects

> **NCT06676891** · — · AVAILABLE · sponsor: **Rznomics, Inc.**

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** RZ-001

## Key facts

- **NCT ID:** NCT06676891
- **Lead sponsor:** Rznomics, Inc.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06676891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06676891, "Expanded Access Program for GBM Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06676891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*